Abstract: Systems and methods are disclosed for process simulation in a cell processing facility. Example methods for processing a patient sample may include recording an identifier code unique to a patient as a unique identifier in a database patient record, collecting a patient sample into a patient sample collection component, checking the sample collection component identity code against a component registry to confirm the correct component (106, 109) is being used for that stage in processing, characterised by: adding the sample collection component identity code as an entry to a custody chain of component identity codes in the patient record, following sample collection, transferring the collection component containing the patient sample to the next operation in the processing where a processing step is performed using a processing component specific to that stage of the processing, and checking the processing component identity code of the specific processing component against the component registry.

Abstract: The present disclosure relates to cell processing techniques. By way of example, a cell processing system may include a plurality of sample processing devices configured to process patient samples and a plurality of readers respectively associated with the plurality of sample processing devices, wherein each reader is configured to read information from tracking devices associated with respective patient samples. The system may also include a controller that uses information from the readers to provide an estimated completion time for a patient sample based on availability of the sample processing devices.

Abstract: The present invention provides improved methods, facilities and systems for parallel processing of biological cellular samples in an efficient and scalable manner. The invention enables parallel processing of biological cellular samples, such as patient samples, in a space and time efficient fashion. Process simulation may be used to determine the optimal arrangement and/or quantity of cell processing equipment needed. The methods, facilities and systems of the invention find particular utility in processing patient samples for use in cell therapy.

Abstract: The present disclosure relates to cell processing techniques. By way of example, a cell processing system may include a plurality of sample processing devices configured to process patient samples and a plurality of readers respectively associated with the plurality of sample processing devices, wherein each reader is configured to read information from tracking devices associated with respective patient samples. The system may also include a controller that uses information from the readers to provide an estimated completion time for a patient sample based on availability of the sample processing devices.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Described is a method of expanding human progenitor cells by suspension culturing under non-static conditions. The culturing method provides a three-dimensional space for the rapid expansion of desirable progenitors. By this method, a new compartment of multipotential progenitor cells has been identified, which give rise under differentiation conditions to progeny including osteoblasts, chondrocytes, myoblasts, adipocytes, and other non-hematopoietic cell types. Their use in cell and tissue-based engineering is described.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the extracellular matrix. Additionally or alternatively, one of the multiple cell types can be delivered to a site in the body via the endogenously produced extracellular matrix components to achieve various therapeutic benefits.

Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.

Abstract: Non-hematopoietic, e.g., mesenchymal progenitor cells, are expanded under non-static, non-adherent conditions in serum-deprived medium.